NCT02418312

Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 228 (actual)
• Sponsor: Kaohsiung Veterans General Hospital. · Academic / Other
• Sex: All
• Age: 20 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Whether H2 receptor antagonist can prevent thienopyridine-related peptic ulcer remains unclear.

Detailed description

The aim of the prospective, randomized study is investigate the efficacy of H2 receptor antagonist in prevention of thienopyridine-related peptic ulcer and gastrointestinal bleeding in patients with an ulcer history. We plan to enroll 236 thienopyridine (clopidogrel or ticlopidine) users with a peptic ulcer history who don't have baseline gastroduodenal ulcers at initial endoscopy . The patients will be randomly assigned to receive either (1) famotidine (40 mg qd) plus thienopyridine used previously or (2) placebo plus thienopyridine treatment alone for 6 months. The ulcer recurrence rate between the treatment gruops will be compared.

Conditions

• Peptic Ulcer

Interventions

Type	Name	Description
DRUG	histamine-2 receptor antagonist	famotidine 40 mg qd plus thienopyridine
DRUG	Placebo	placebo plus thienopyridine

Timeline

• Start date: 2012-01-01
• Primary completion: 2017-10-01
• Completion: 2017-10-01
• First posted: 2015-04-16
• Last updated: 2019-03-11
• Results posted: 2019-03-11

Locations

1 site across 1 country: Taiwan